Back to Journals » HIV/AIDS - Research and Palliative Care » Volume 11

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection

Authors Zamora FJ, Dowers E, Yasin F, Ogbuagu O

Received 2 August 2019

Accepted for publication 12 September 2019

Published 23 October 2019 Volume 2019:11 Pages 255—263

DOI https://doi.org/10.2147/HIV.S216067

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Melinda Thomas

Peer reviewer comments 3

Editor who approved publication: Professor Bassel Sawaya


Francis J Zamora,1,2 Ellen Dowers,2 Faiza Yasin,3 Onyema Ogbuagu3

1Department of Pharmacy Services, Broward Health Medical Center, Fort Lauderdale, FL, USA; 2Department of Pharmacy Services, Yale-New Haven Hospital, New Haven, CT, USA; 3Section of Infectious Diseases, Yale AIDS Program, Yale University School of Medicine, New Haven, CT, USA

Correspondence: Onyema Ogbuagu
Section of Infectious Diseases, Yale AIDS Program, Yale University School of Medicine, 135 College Street, Suite 323, New Haven, CT 06510, USA
Tel +1 516-281-4557
Fax 1 203 737 4051
Email onyema.ogbuagu@yale.edu

Abstract: There have been remarkable advances in drug development for the treatment of HIV-1 infection. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development of long-acting antiretroviral (ARV) drug formulations, the treatment of HIV has and will become much more tolerable and less complicated for patients. In addition, and appropriately, there is a focus on reducing short- and long-term toxicities of treatment while maintaining robust efficacy. One of such approaches includes 2-drug regimen constructs that contain and retain effective ARV compounds while excluding components that have relatively unfavorable toxicity profiles. The first-ever 2-drug regimen approved for the treatment of HIV-1 infection for treatment-naive people living with HIV (PLWH), consisting of the integrase inhibitor dolutegravir (DTG) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC), is reviewed in this paper. The chemical composition and properties, pharmacokinetic and pharmacodynamics profile, and clinical trial data on efficacy and safety of DTG/3TC are presented. An expert opinion aims to highlight important considerations for the use of DTG/3TC in the context of existing and emerging ARV options.

Keywords: dolutegravir, lamivudine, combination antiretroviral therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]